Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:03AM ET
2.03
Dollar change
-0.01
Percentage change
-0.49
%
IndexRUT P/E- EPS (ttm)-1.38 Insider Own35.96% Shs Outstand95.64M Perf Week-30.24%
Market Cap195.87M Forward P/E- EPS next Y-1.80 Insider Trans0.00% Shs Float61.79M Perf Month-30.24%
Income-123.43M PEG- EPS next Q-0.42 Inst Own47.11% Short Float6.67% Perf Quarter-28.77%
Sales64.70M P/S3.03 EPS this Y-21.90% Inst Trans57.20% Short Ratio5.46 Perf Half Y-15.42%
Book/sh1.08 P/B1.87 EPS next Y-7.93% ROA-38.88% Short Interest4.12M Perf Year-15.77%
Cash/sh2.20 P/C0.92 EPS next 5Y2.70% ROE-84.75% 52W Range1.54 - 4.27 Perf YTD-39.58%
Dividend Est.- P/FCF- EPS past 5Y-12.83% ROI-67.38% 52W High-52.46% Beta0.52
Dividend TTM- Quick Ratio3.18 Sales past 5Y53.46% Gross Margin91.32% 52W Low31.82% ATR (14)0.26
Dividend Ex-Date- Current Ratio3.18 EPS Y/Y TTM-27.66% Oper. Margin-200.15% RSI (14)29.24 Volatility11.01% 8.28%
Employees330 Debt/Eq0.82 Sales Y/Y TTM-50.42% Profit Margin-190.76% Recom1.00 Target Price14.00
Option/ShortYes / Yes LT Debt/Eq0.77 EPS Q/Q31.60% Payout- Rel Volume0.49 Prev Close2.04
Sales Surprise275.94% EPS Surprise30.05% Sales Q/Q148.68% EarningsMar 07 AMC Avg Volume755.33K Price2.03
SMA20-29.11% SMA50-37.73% SMA200-23.93% Trades Volume48,002 Change-0.49%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Initiated H.C. Wainwright Buy $15
Jan-07-22Initiated Cantor Fitzgerald Overweight $24
May-18-21Initiated BTIG Research Buy $40
Aug-04-20Initiated William Blair Outperform
Aug-04-20Initiated Piper Sandler Overweight $30
Aug-04-20Initiated BofA Securities Buy $20
Today 08:00AM
Apr-17-24 09:00AM
Apr-08-24 12:00PM
Apr-01-24 04:05PM
Mar-25-24 04:05PM
04:05PM Loading…
Mar-19-24 04:05PM
Mar-13-24 04:05PM
Mar-07-24 10:53PM
10:45PM
06:55PM
04:07PM
Mar-04-24 04:05PM
Jan-04-24 08:00AM
Dec-10-23 12:00PM
Nov-17-23 01:08PM
04:05PM Loading…
Nov-09-23 04:05PM
Nov-07-23 08:00AM
Nov-02-23 10:00AM
09:01AM
Oct-16-23 12:00PM
Oct-09-23 04:30PM
Oct-03-23 05:00PM
Sep-05-23 08:00AM
Aug-10-23 06:02AM
Aug-08-23 05:40PM
04:05PM
Aug-07-23 09:01AM
09:00AM
Jul-31-23 08:23AM
Jul-05-23 08:00AM
08:00AM Loading…
Jun-26-23 08:00AM
Jun-01-23 08:00AM
May-23-23 08:00AM
May-22-23 08:00AM
May-18-23 08:00AM
May-11-23 06:11AM
May-10-23 12:00PM
May-09-23 07:05PM
04:05PM
May-02-23 04:30PM
May-01-23 08:00AM
Apr-17-23 06:48AM
Apr-13-23 08:00AM
Apr-11-23 04:05PM
08:00AM
Apr-03-23 07:09AM
Mar-09-23 06:05PM
04:05PM
Mar-01-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 06:50AM
Feb-15-23 08:50AM
Feb-14-23 08:00AM
Feb-08-23 08:00AM
Jan-31-23 04:05PM
Jan-27-23 08:50AM
Jan-25-23 11:16AM
Jan-10-23 08:50AM
Jan-04-23 02:51PM
Dec-15-22 08:50AM
Dec-11-22 10:30AM
Dec-06-22 09:55AM
06:00AM
Nov-10-22 06:45PM
04:05PM
Nov-08-22 08:00AM
Nov-03-22 09:00AM
09:00AM
Oct-25-22 06:11AM
Oct-05-22 08:09AM
Sep-14-22 06:57AM
Sep-07-22 04:05PM
Aug-11-22 04:05PM
Aug-08-22 04:05PM
Aug-04-22 08:00AM
07:00AM
Aug-03-22 04:01PM
09:02AM
07:30AM
Jul-26-22 08:00AM
Jun-29-22 04:05PM
Jun-02-22 08:00AM
May-18-22 08:00AM
May-17-22 08:00AM
May-15-22 08:37AM
May-12-22 06:05PM
04:05PM
May-09-22 08:22AM
May-02-22 04:30PM
Apr-28-22 08:00AM
Mar-14-22 12:48PM
Mar-10-22 06:35PM
04:05PM
Mar-01-22 07:47PM
Feb-23-22 08:00AM
Feb-22-22 08:00AM
Feb-17-22 08:00AM
Feb-09-22 08:00AM
Jan-10-22 08:00AM
Jan-05-22 10:17AM
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.